Isabella Feierberg
About Isabella Feierberg
Isabella Feierberg is an Associate Director of Cheminformatics at Jnana Therapeutics, with a strong academic background and extensive experience in computational chemistry. She has held various positions at AstraZeneca and has a PhD from Uppsala University.
Work at Jnana Therapeutics
Isabella Feierberg has been serving as the Associate Director of Cheminformatics at Jnana Therapeutics since 2021. In this role, she contributes her expertise in cheminformatics to support the company's drug discovery efforts. Jnana Therapeutics focuses on harnessing the power of chemistry and biology to develop innovative therapies. Feierberg's position involves leading initiatives that integrate computational methods with experimental data to enhance the drug development process.
Education and Expertise
Isabella Feierberg holds a PhD from Uppsala University, where she studied from 1998 to 2003. She also earned a Master of Science (M Sc) degree in civil engineering from the same institution, completing her studies from 1992 to 1998. Additionally, she studied at Göteborgs universitet / University of Gothenburg, achieving 7.5 hp in 2012 over an 11-month period. Her educational background provides a strong foundation in computational chemistry and cheminformatics.
Background
Isabella Feierberg began her career in 1998 as a Computational Chemist at Pharmacia & Upjohn in Uppsala, Sweden. She later pursued her PhD at Uppsala University, which she completed in 2003. Following her doctoral studies, she worked at AstraZeneca in various roles, including PostDoctoral Scientist in Computational Chemistry and Senior Research Scientist in Computational Chemistry/Cheminformatics. She held positions at AstraZeneca from 2003 to 2018, contributing to hit discovery and molecular AI.
Professional Experience at AstraZeneca
Feierberg's tenure at AstraZeneca spanned multiple roles and locations. She worked as a PostDoctoral Scientist in Computational Chemistry for six months in 2003, followed by an 11-year stint as a Senior Research Scientist in Mölndal, Sweden. From 2015 to 2018, she served as Associate Principal Scientist in Hit Discovery in Gothenburg, and later as Associate Principal Scientist in Molecular AI in Waltham, Massachusetts, from 2018 to 2021. Her work at AstraZeneca focused on advancing computational methods in drug discovery.